Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical , deepening their use of artificial intelligence to accelerate drug discovery.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nabla Bio, a biotechnology company pioneering de novo therapeutics design with generative AI, today announced a new, multi-year research collaboration with Takeda. Under the terms of the agreement, Nabla Bio will receive double-digit millions in upfront and research cost payments and is eligible to receive success-based payments that may exceed $1 billion in t...

Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will discontinue its cell therapy research and look for a partner to advance candidates under development.

Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development.

Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already broken ground on U.S. manufacturing plants.

Takeda (TAK) offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. TAK's pipeline includes first-in-class and best-in-class candidates, but faces commercialization and competitive risks, especially with high debt levels. Financial restructuring, margin expansion, and debt reduction are critical for TAK's valuation recovery and future d...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to building climate-resilient health systems in low- and middle-income countries around the world. Amid rising temperatures and extreme weather even...

High-yield dividend stocks entice investors with payouts two to four times higher than the S&P 500's 1.4% average yield. But high yield often signals trouble -- sluggish growth, stretched payout ratios, or sector headwinds.